ArticleCurrent stem cell research & therapy2025
PLGA-hucMSC-Ex Ameliorates Colitis by Reversing Epithelial-mesenchymal Transition.
Article in Current stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mesenchymal Stem Cells Derived Extracellular Vesicles in Inflammatory Bowel Disease: Therapeutic Efficacy and Bioengineering Applications.International journal of nanomedicine · 2026Review
- Application of Human Umbilical Cord Mesenchymal Stem Cells and Their Derived Exosomes in Gastrointestinal Diseases.International journal of nanomedicine · 2026Review
- Role of exosomes in gastrointestinal physiology and pathophysiology.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHuman umbilical cord mesenchymal stem cell-derived exosomes (hucMSC-Exs) have been found to exhibit therapeutic effects on inflammatory bowel disease (IBD). However, due to the harsh environment of the gastrointestinal tract, exosomes, as a type of biological drug or carrier of bio-active substances, are still delivered by tail vein injection.
methodIn this study, hucMSC-Ex were coated with poly (lactic-co-glycolic acid) (PLGA) polymer to form microparticles, PLGA-hucMSC-Ex, by double emulsion method.
resultsThe oral administration of PLGA-hucMSC-Ex particles alleviated inflammation in the mice model of IBD by reversing IBD-induced epithelial-mesenchymal transition (EMT).
conclusionThis provides an alternative to exploring IBD treatments, with potential clinical application to relieve IBD in patients.
Indexed as
Identifiers
40207821What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.